In the first step, CLL patients were divided into two main groups according to their CD19, CD5, and ZAP70 expression (CD19+CD5+ZAP+ and CD19+CD5+ZAP-). This evidence concerns the gene ZAP70 and B-cell chronic lymphocytic leukemia.